DYRK1A and cancer: Surprisingly, perhaps, most of the reports on DYRK1A in the cancer literature describe the development and use of DYRK1A inhibitors as anti-cancer therapeutics (110, 111), and report that increased DYRK1A activity in cancer drives oncogenesis.